Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity

Journal of General Virology

Volumn 86, Issue 9, 2005, Pages 2401-2410

  Lauterbach, Henning ^a,d   Ried, Christine ^a   Epstein, Alberto L ^b   Marconi, Peggy ^c   Brocker, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF FERRARA   (Italy)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1;

EID: 23844494246     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81104-0     Document Type: Article

References (65)

1. Advani, S. J., Weichselbaum, R. R., Whitley, R. J. & Roizman, B. (2002). Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect 8, 551-563.
2. Ahmad, A., Sharif-Askari, E., Fawaz, L. & Menezes, J. (2000). Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 74, 7196-7203.
3. Brockman, M. A. & Knipe, D. M. (2002). Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 76, 3678-3687.
4. Bukowski, J. F., Morita, C. T. & Brenner, M. B. (1994). Recognition and destruction of virus-infected cells by human gamma delta CTL. J Immunol 153, 5133-5140.
5. Burton, E. A., Wechuck, J. B., Wendell, S. K., Goins, W. F., Fink, D. J. & Glorioso, J. C. (2001). Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 19, 358-377.
6. Cassady, K. A., Gross, M. & Rolzman, B. (1998). The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 72, 7005-7011.
7. Chahlavi, A., Rabkin, S., Todo, T., Sundaresan, P. & Martuza, R. (1999). Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6, 1751-1758.
8. Coffin, R. S., Thomas, S. K., Thomas, N. S. & 11 other authors (1998). Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry. Gene Ther 5, 718-722.
9. Cunningham, A. L., Mindel, A. & Dwyer, D. E. (2000). Global epidemiology of sexually transmitted diseases. In Sexually Transmitted Disease, pp. 3-42. Edited by L. R. Stanberry & D. Bernstein. San Diego: Academic Press.
10. Da Costa, X. J., Brockman, M. A., Alicot, E., Ma, M., Fischer, M. B., Zhou, X., Knipe, D. M. & Carroll, M. C. (1999). Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci U S A 96, 12708-12712.
11. Deshpande, S. P., Kumaraguru, U. & Rouse, B. T. (2000). Why do we lack an effective vaccine against herpes simplex virus infections? Microbes Infect 2, 973-978.
12. Etlinger, H. M. & Altenburger, W. (1991). Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 9, 470-472.
13. Farrell, H. E., McLean, C. S., Harley, C., Efstathiou, S., Inglis, S. & Minson, A. C. (1994). Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 68, 927-932.
14. Feduchi, E., Alonso, M. A. & Carrasco, L. (1989). Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol 63, 1354-1359.
15. Friedman, H. M., Wang, L., Pangburn, M. K., Lambris, J. D. & Lubinski, J. (2000). Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J Immunol 165, 4528-4536.
16. Fries, L. F., Friedman, H. M., Cohen, G. H., Eisenberg, R. J., Hammer, C. H. & Frank, M. M. (1986). Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol 137, 1636-1641.
17. Geiss, B. J., Smith, T. J., Leib, D. A. & Morrison, L. A. (2000). Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. J Virol 74, 11137-11144.
18. Hardy, W. R. & Sandri-Goldin, R. M. (1994). Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect. J Virol 68, 7790-7799.
19. Herrlinger, U., Kramm, C. M., Aboody-Guterman, K. S. & 9 other authors (1998). Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 5, 809-819.
20. Hill, A., Jugovic, P., York, I., Russ, G., Bennink, J., Yewdell, J., Ploegh, H. & Johnson, D. (1995). Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411-415.
21. Hocknell, P. K., Wiley, R. D., Wang, X., Evans, T. G., Bowers, W. J., Hanke, T., Federoff, H. J. & Dewhurst, S. (2002). Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 76, 5565-5580.
22. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. & Carbone, F. R. (1994). T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27.
23. Huard, J., Goins, W. F. & Glorioso, J. C. (1995). Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Ther 2, 385-392.
24. Johnson, D. C. & Feenstra, V. (1987). Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin. J Virol 61, 2208-2216.
25. Kadowaki, N., Antonenko, S., Lau, J. Y. & Liu, Y. J. (2000). Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 192, 219-226.
26. Keadle, T. L., Morrison, L. A., Morris, J. L., Pepose, J. S. & Stuart, P. M. (2002). Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection. J Virol 76, 3615-3625.
27. Kleindienst, P., Wiethe, C., Lutz, M. B. & Brocker, T. (2005). Simultaneous induction of CD4 T cell tolerance and CD8 T cell immunity by semimature dendritic cells. J Immunol 174, 3941-3947.
28. Kodukula, P., Liu, T., Rooijen, N. V., Jager, M. J. & Hendricks, R. L. (1999). Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J Immunol 162, 2895-2905.
29. Koelle, D. M. & Corey, L. (2003). Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16, 96-113.
30. Krisky, D. M., Wolfe, D., Goins, W. F., Marconi, P. C., Ramakrishnan, R., Mata, M., Rouse, R. J., Fink, D. J. & Glorioso, J. C. (1998). Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 5, 1593-1603.
31. Kurts, C., Miller, J. F., Subramaniam, R. M., Carbone, F. R. & Heath, W. R. (1998). Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188, 409-414.
32. Kurts, C., Sutherland, R. M., Davey, G., Li, M., Lew, A. M., Blanas, E., Carbone, F. R., Miller, J. F. & Heath, W. R. (1999). CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 96, 12703-12707.
33. Lauterbach, H., Kerksiek, K. M., Busch, D. H. & 7 other authors (2004). Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol 78, 4020-4028.
34. Li, Z., Dullmann, J., Schiedlmeier, B. & 12 other authors (2002). Murine leukemia induced by retroviral gene marking. Science 296, 497.
35. Littler, E., Purifoy, D., Minson, A. & Powell, K. L. (1983). Herpes simplex virus non-structural proteins. III. Function of the major DNA-binding protein. J Gen Virol 64, 983-995.
36. Mandl, S., Hix, L. & Andino, R. (2001). Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors. J Virol 75, 622-627.
37. Melchjorsen, J., Pedersen, F. S., Mogensen, S. C. & Paludan, S. R. (2002). Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0. J Virol 76, 2780-2788.
38. Mellerick, D. M. & Fraser, N. W. (1987). Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology 158, 265-275.
39. Mikloska, Z. & Cunningham, A. L. (1998). Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 79, 353-361.
40. Mikloska, Z., Kesson, A. M., Penfold, M. E. & Cunningham, A. L. (1996). Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma. J Infect Dis 173, 7-17.
41. Mikloska, Z., Bosnjak, L. & Cunningham, A. L. (2001). Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J Virol 75, 5958-5964.
42. Moriuchi, S., Krisky, D. M., Marconi, P. C., Tamura, M., Shimizu, K., Yoshimine, T., Cohen, J. B. & Glorioso, J. C. (2000). HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther 7, 1483-1490.
43. Morrison, L. A. & Knipe, D. M. (1994). Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 68, 689-696.
44. Morrison, L. A. & Knipe, D. M. (1996). Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology 220, 402-413.
45. Morrison, L. A. & Knipe, D. M. (1997). Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology 239, 315-326.
46. Murphy, C. G., Lucas, W. T., Means, R. E. & 7 other authors (2000). Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 74, 7745-7754.
47. Nagashunmugam, T., Lubinski, J., Wang, L., Goldstein, L. T., Weeks, B. S., Sundaresan, P., Kang, E. H., Dubin, G. & Friedman, H. M. (1998). In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72, 5351-5359.
48. Neumann, J., Eis-Hubinger, A. M. & Koch, N. (2003). Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion. J Immunol 171, 3075-3083.
49. Nopora, A. & Brocker, T. (2002). Bcl-2 controls dendritic cell longevity in vivo. J Immunol 169, 3006-3014.
50. Ogg, P. D., McDonell, P. J., Ryckman, B. J., Knudson, C. M. & Roller, R. J. (2004). The HSV-1 Us3 protein kinase is sufficient to block apoptosis induced by overexpression of a variety of Bcl-2 family members. Virology 319, 212-224.
51. Palmer, J. A., Branston, R. H., Lilley, C. E., Robinson, M. J., Groutsi, F., Smith, J., Latchman, D. S. & Coffin, R. S. (2000). Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol 74, 5604-5618.
52. Papp, Z., Babiuk, L. A. & Baca-Estrada, M. E. (1999). The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine 17, 933-943.
53. Parr, M. J., Wen, P. Y., Schaub, M., Khoury, S. J., Sayegh, M. H. & Fine, H. A. (1998). Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol 4, 194-203.
54. Pollara, G., Speidel, K., Samady, L., Rajpopat, M., McGrath, Y., Ledermann, J., Coffin, R. S., Katz, D. R. & Chain, B. (2003). Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. J Infect Dis 187, 165-178.
55. Pushko, P., Parker, M., Ludwig, G. V., Davis, N. L., Johnston, R. E. & Smith, J. F. (1997). Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239, 389-401.
56. Samady, L., Costigliola, E., MacCormac, L. & 7 other authors (2003). Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs-HSV vectors for dendritic cell-mediated immunotherapy. J Virol 77, 3768-3776.
57. Schulick, A. H., Vassalli, G., Dunn, P. F., Dong, G., Rade, J. J., Zamarron, C. & Dichek, D. A. (1997). Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 99, 209-219.
58. Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S. & Liu, Y. J. (1999). The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835-1837.
59. Sloan, D. D., Zahariadis, G., Posavad, C. M., Pate, N. T., Kussick, S. J. & Jerome, K. R. (2003). CTL are inactivated by herpes simplex virus-infected cells expressing a viral protein kinase. J Immunol 171, 6733-6741.
60. Stanberry, L. R., Cunningham, A. L., Mindel, A., Scott, L. L., Spruance, S. L., Aoki, F. Y. & Lacey, C. J. (2000). Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 30, 549-566.
61. Thomas, C. E., Ehrhardt, A. & Kay, M. A. (2003). Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4, 346-358.
62. Wade-Martins, R., Saeki, Y. & Antonio Chiocca, E. (2003). Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 7, 604-612.
63. Wallace, M. E., Keating, R., Heath, W. R. & Carbone, F. R. (1999). The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 73, 7619-7626.
64. Wang, X., Wiley, R. D., Evans, T. G., Bowers, W. J., Federoff, H. J. & Dewhurst, S. (2003). Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine 21, 2288-2297.
65. Wu, C. A., Nelson, N. J., McGeoch, D. J. & Challberg, M. D. (1988). Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis. J Virol 62, 435-443.